botensilimab,balstilimab
agenus
['botensilimab', 'imab ']
botensilimab demonstrates unprecedented repsonses in mss-crc (orr: 22%), platinum refractory/resistant ovarian cancer (orr: 26%), sarcoma (orr:42%) and pd-(l)1 r/r nsclc (orr: 50%). #sitc22 #immunotherapy #cancer #cure 